No Data
Innovative drug concepts are generally rising, Beigene (06160) rose 3.14%. Institutions pointed out that overseas authorization and heavy innovation will be the catalyst for industry investment.
Innovative drug concept rose, Remegen (09995) rose by 4.14%, Beigene (06160) rose by 3.14%, Akeso (09926) rose by 1.84%, Innovent bio (01801) rose by 1.82%, Hutchmed (china) (00013) rose by 1.82%, Frontage (01521) rose by 1.35%, Canbridge Life Sciences-B (02162) rose by 0.63%, Innocare (09969) rose by 0.45%. Sinolink Securities indicated that the performance of the innovative drug companies has shown a clear trend of improvement based on the disclosed interim reports. Beigene and Hutchmed (china) pharmaceutical both performed well.
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Innovative drug concept rises against the market, with Innovent Bio (01801) increasing by 3.85%. The State Drug Administration has agreed to carry out related evaluation and approval pilots in Beijing and Shanghai.
Jingu Wealth News | Innovative drug concept rises against the trend, with Remegen (09995) up 6.15%, Innovent Bio (01801) up 3.85%, Akeso (09926) up 2.84%, Hutchmed (China) (00013) up 2.55%, Frontage (01521) up 2.41%, Innocare (09969) up 1.96%, Canbridge Life Sciences-B (02162) up 1.86%, and BeiGene (06160) up 1.21%. The National Medical Products Administration has approved the pilot program for optimizing clinical trial evaluation and approval of innovative drugs in Beijing and Shanghai after review.
Hong Kong stock concept tracking | National Medical Products Administration approved the pilot program of optimizing the clinical trial review and approval of innovative drugs in Peking and Shanghai, and innovative drugs are expected to outperform other s
The pharmaceutical industry is expected to see overall year-on-year improvement and quarter-on-quarter growth in performance in the second half of the year.
CSC: Rich pipeline of IL-17A and other target drugs, related drugs are expected to gradually achieve domestic production.
There is a rich pipeline of targeted drugs for IL-17A, IL-4R, JAK, IL-23, and other targets, some of which have already been approved for domestic pipelines or applied for approval. Relevant drugs are expected to gradually achieve domestic production in the treatment of autoimmune diseases in China.
China Securities Co., Ltd. expects that the "expanding domestic demand" trade will gradually grow, covering cyclical and growth stocks.
China Securities Co.,Ltd. released a research report stating that it is expected that the 'expanding domestic demand' trade will gradually grow, covering both cyclical and growth stocks.
No Data
